Optiver Holding
FATE icon

Optiver Holding’s Fate Therapeutics FATE Stock Holding History

Optiver Holding’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,132
Closed -$1.11K – 2457
2025
Q4 		$1.11K Sell
1,132
-1,659
-59% -$1.99K ﹤0.01% 2199
2025
Q3 		$3.52K Buy
2,791
+1,662
+147% +$1.79K ﹤0.01% 2069
2025
Q2 		$1.26K Buy
1,129
+2
+0.2% +$2 ﹤0.01% 1377
2025
Q1 		$890 Buy
1,127
+557
+98% +$683 ﹤0.01% 1288
2024
Q4 		$940 Buy
+570
New +$1.44K ﹤0.01% 987
2024
Q3 		– Sell
-858
Closed -$2.81K – 994
2024
Q2 		$2.81K Buy
+858
New +$3.76K ﹤0.01% 829

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Optiver Holding's FATE Position: Q1 2026 in Review

Optiver Holding sold out of Fate Therapeutics (FATE) in Q1 2026, closing a stake of 1,132 shares — an estimated $1.11K sold.

Optiver Holding first reported a position in FATE in Q2 2024 and held it in 6 quarters. The position peaked at $3.52K in Q3 2025. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Optiver Holding reported no remaining Fate Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Optiver Holding sold 1,132 Fate Therapeutics shares in Q1 2026, an estimated $1.11K.
  • Optiver Holding first reported a position in Fate Therapeutics in Q2 2024 and held it in 6 quarters.
  • Optiver Holding's Fate Therapeutics position peaked at $3.52K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.